NCT00127153
Completed
Phase 3
A Comparative Study in Healthy Adults of the Safety, Tolerability, and Immunogenicity of V110 Formulated With Either All New Process Polysaccharides or All Current Process Polysaccharides
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Healthy
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 130
- Primary Endpoint
- Immunogenicity
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
The purpose of this trial is to evaluate the safety, tolerability, and immunogenicity of an investigational pneumococcal vaccine in healthy adults.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Males and females in good health, ages 20-40, with no history of pneumococcal vaccination
Exclusion Criteria
- •Subjects with a recent febrile illness
- •Known or suspected immune dysfunction, conditions associated with immunosuppression, and receipt of immunosuppressive chemotherapy, including long-term corticosteroid therapy
Outcomes
Primary Outcomes
Immunogenicity
Secondary Outcomes
- Safety
Similar Trials
Completed
Phase 3
Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)Hepatitis BNCT00440531Merck Sharp & Dohme LLC540
Completed
Phase 1
Clinical Trial of Bilhvax,a Vaccine Candidate Against SchistosomiasisSchistosomiasisBilharziasisUrinary SchistosomiasisNCT01512277University Hospital, Lille24
Completed
Phase 1
Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected AdultsHIV InfectionsNCT00384787National Institute of Allergy and Infectious Diseases (NIAID)90
Recruiting
Early Phase 1
Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid TumorsNCT06577532Ruijin Hospital56
Completed
Phase 3
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and OlderInfluenzaNCT00979602GlaxoSmithKline4,048